Jump to content

Martin Landray: Difference between revisions

Add links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous edit
Content deleted Content added
VisualWikitext
No edit summary
Citation bot (talk | contribs)
Bots
5,359,389 edits
Add: date. | Use this bot. Report bugs. | Suggested by Grimes2 | Category:Academics of the University of Oxford | #UCB_Category 96/637
 
(37 intermediate revisions by 18 users not shown)
Line 1: Line 1:
{{short description|Professor of Emerging Infectious Diseases and Global Health}}
{{short description|British epidemiologist and professor (born c. 1968)}}
{{Like resume|date=October 2020}}
{{Infobox scientist
{{Infobox scientist
| honorific_prefix = [[Sir]]
| name = Martin Landray
| honorific_suffix =
| name = Martin Landray
| birth_date = {{circa|{{birth year and age|1968}}}}
⚫
| alma_mater = [[University of Birmingham]]
| birth_place =
⚫
| workplaces = [[University of Oxford]]
| death_date =
⚫
| website = {{URL|https://www.bdi.ox.ac.uk/Team/martin-landray}}
| death_place =
| honorific_suffix =
⚫
| alma_mater = [[Abingdon School]]<br />[[University of Birmingham]]
⚫
| workplaces = [[University of Oxford]]
⚫
| website = {{URL|https://www.bdi.ox.ac.uk/Team/martin-landray}}
}}
}}
'''Martin Landray''' is a British [[physician]], [[epidemiologist]] and [[data scientist]] who serves as a ''Professor of Medicine & Epidemiology'' at the [[University of Oxford]]. Landray has specialist knowledge and experience at designing, conducting and analysing large-scale [[randomised control trial|randomised control trials]]; including practice-changing international trials that have recruited over 100,000 individuals.<ref>{{cite web |title=Why the UK is ahead of the curve in the global race to find coronavirus treatments - Q&A with Martin Landray |url=https://reaction.life/why-the-uk-is-ahead-of-the-curve-in-the-global-race-to-find-coronavirus-treatments-qa-with-martin-landray/ |website=Reaction |date=22 April 2020}}</ref> Landray previously led the health informatics team that enabled the collection and management of data for the [[UK Biobank]] on over half a million people.<ref>{{cite news |title=The challenge of saving lives with 'big data' |url=https://www.bbc.co.uk/news/health-35491177 |accessdate=16 October 2020 |work=BBC News |date=7 February 2016}}</ref>
'''Sir Martin Jonathan Landray''' (born {{circa|1968}}) is a British [[physician]], [[epidemiologist]] and [[data scientist]] who serves as a ''Professor of Medicine & Epidemiology'' at the [[University of Oxford]]. Landray designs, conducts and analyses large-scale [[randomised control trial]]s; including practice-changing international trials that have recruited over 100,000 individuals.<ref>{{cite web |title=Why the UK is ahead of the curve in the global race to find coronavirus treatments - Q&A with Martin Landray |url=https://reaction.life/why-the-uk-is-ahead-of-the-curve-in-the-global-race-to-find-coronavirus-treatments-qa-with-martin-landray/ |website=Reaction |date=22 April 2020}}</ref> Landray previously led the health informatics team that enabled the collection and management of data for the [[UK Biobank]] on over half a million people.<ref>{{cite news |title=The challenge of saving lives with 'big data' |url=https://www.bbc.co.uk/news/health-35491177 |access-date=16 October 2020 |work=BBC News |date=7 February 2016}}</ref>


==Early life and education==
⚫
Landray serves as co-chief investigator of the [[RECOVERY Trial]] into treatment drugs for [[COVID-19]] (the largest such clinical trial in the world) alongside [[Peter Horby]].<ref>{{Cite web|title=ISRCTN - ISRCTN50189673: A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus)|url=http://www.isrctn.com/ISRCTN50189673|access-date=2020-09-06|website=www.isrctn.com|language=en}}</ref><ref>{{cite web |title=Large-scale trial for coronavirus drugs launches in UK |url=https://www.clinicaltrialsarena.com/news/coronavirus-trial-uk-treatments/ |website=Clinical Trials Arena |accessdate=7 September 2020 |date=6 April 2020}}</ref><ref>{{cite web |title=Managing clinical trials during the pandemic — Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences |url=https://www.ndorms.ox.ac.uk/news/managing-clinical-trials-during-the-pandemic |website=www.ndorms.ox.ac.uk |accessdate=7 September 2020}}</ref> In June 2020, the trial discovered the first known life-saving COVID-19 drug, [[Dexamethasone]].<ref>{{Cite web|title=Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19 {{!}} University of Oxford|url=https://www.ox.ac.uk/news/2020-06-16-low-cost-dexamethasone-reduces-death-one-third-hospitalised-patients-severe|access-date=2020-09-06|website=www.ox.ac.uk}}</ref><ref>{{Cite web|title=Prime Minister's statement on coronavirus (COVID-19): 16 June 2020|url=https://www.gov.uk/government/speeches/pm-statement-at-the-coronavirus-press-conference-16-june-2020|access-date=2020-09-06|website=GOV.UK|language=en}}</ref><ref>{{cite journal | vauthors = Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, Chadwick D, Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Jeffery K, Montgomery A, Rowan K, Juszczak E, Baillie JK, Haynes R, Landray MJ | display-authors = 6 | title = Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report | journal = The New England Journal of Medicine | volume = 0 | date = July 2020 | pmid = 32678530 | pmc = 7383595 | doi = 10.1056/NEJMoa2021436 }}</ref> The trial also showed that [[Tocilizumab]] further reduces the risk of death for the sickest patients with COVID-19.<ref>{{cite journal |title=RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial |pmid=33933206}}</ref> The trial was first to find negative results for [[Hydroxychloroquine]],<ref>{{cite journal |last1=Group |first1=The RECOVERY Collaborative |title=Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19 |journal=New England Journal of Medicine |date=8 October 2020 |volume=383 |issue=21 |pages=2030–2040 |doi=10.1056/NEJMoa2022926 |pmid=33031652 |pmc=7556338 |url=https://www.nejm.org/doi/10.1056/NEJMoa2022926 |accessdate=16 October 2020 |language=en}}</ref> [[Lopinavir/ritonavir]],<ref>{{cite journal |last1=Horby |first1=Peter W. |last2=Mafham |first2=Marion |last3=Bell |first3=Jennifer L. |last4=Linsell |first4=Louise |last5=Staplin |first5=Natalie |last6=Emberson |first6=Jonathan |last7=Palfreeman |first7=Adrian |last8=Raw |first8=Jason |last9=Elmahi |first9=Einas |last10=Prudon |first10=Benjamin |last11=Green |first11=Christopher |last12=Carley |first12=Simon |last13=Chadwick |first13=David |last14=Davies |first14=Matthew |last15=Wise |first15=Matthew P. |last16=Baillie |first16=J. Kenneth |last17=Chappell |first17=Lucy C. |last18=Faust |first18=Saul N. |last19=Jaki |first19=Thomas |last20=Jefferey |first20=Katie |last21=Lim |first21=Wei Shen |last22=Montgomery |first22=Alan |last23=Rowan |first23=Kathryn |last24=Juszczak |first24=Edmund |last25=Haynes |first25=Richard |last26=Landray |first26=Martin J. |title=Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial |journal=The Lancet |date=5 October 2020 |volume=0 |issue=10259 |pages=1345–1352 |doi=10.1016/S0140-6736(20)32013-4 |pmid=33031764 |pmc=7535623 |url=https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32013-4/fulltext |accessdate=16 October 2020 |language=English |issn=0140-6736}}</ref> [[Azithromycin]],<ref>{{cite journal |title=Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial |pmid=33545096}}</ref> [[Convalescent plasma]],<ref>{{cite journal |doi=10.1101/2021.03.09.21252736}}</ref><ref>{{cite journal |title=Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial |doi=10.1101/2021.03.09.21252736}}</ref> and [[Colchicine]].<ref>[https://www.recoverytrial.net/news/recovery-trial-closes-recruitment-to-colchicine-treatment-for-patients-hospitalised-with-covid-19]</ref> The trial continues to study [[REGN-COV2]] and [[Baricitinib]].<ref>{{cite web |title=Welcome — RECOVERY Trial |url=https://www.recoverytrial.net/ |website=www.recoverytrial.net |accessdate=16 October 2020}}</ref>
Landray was born the son of a general practitioner, Bob Landray and an anaesthetist, Margaret Bray.<ref>{{cite web |url=https://atom.bamptonarchive.org/index.php/the-landray-family-a-family-of-doctors |title=The Landry Family |website=Bampton Archives |access-date=14 June 2021}}</ref> He was educated at [[Abingdon School]] in [[Abingdon-on-Thames]], Oxfordshire, from 1982 until 1987. He was a prefect and played rugby and cricket.<ref>{{cite web|url=https://www.abingdon.org.uk/uploads/school/files/abingdonian/1987_December_V018_N005.pdf#page=7|title=Prefects|website=The Abingdonian|access-date=14 June 2021}}</ref><ref>{{cite web|url=https://www.abingdon.org.uk/uploads/school/files/abingdonian/1986_December_V018_N004.pdf#page=23|title=Music report|website=The Abingdonian|access-date=14 June 2021}}</ref> After Abingdon he went on to study medicine at the [[University of Birmingham]], returning later for specialist training in Clinical Pharmacology & Therapeutics, and General Internal Medicine.<ref>{{cite web|url=https://www.ndph.ox.ac.uk/team/martin-landray|title=Martin Landray|website=Nuffield Department of Population Health|access-date=14 June 2021}}</ref>


==Career==
He has been a member of the been one of the leaders of the Clinical Trial Transformation Initiative's<ref>[https://www.ctti-clinicaltrials.org/]</ref> risk-based monitoring,<ref>[https://www.ctti-clinicaltrials.org/sites/www.ctti-clinicaltrials.org/files/recommendations/monitoring-recommendations.pdf]</ref> quality-by-design,<ref>[https://www.ctti-clinicaltrials.org/projects/quality-design]</ref> and mobile clinical trial projects<ref>{{cite news |last1=Entis |first1=Laura |title=Can smartphone drug trials improve medical care? |url=https://www.theguardian.com/lifeandstyle/2016/jan/27/smartphone-mobile-drug-trials-fda-pfizer-ctti-depression-us-health |accessdate=16 October 2020 |work=The Guardian |date=27 January 2016}}</ref> and has driven work encourage the creation of new regulatory guidelines for clinical trials.<ref>{{cite journal |url=http://eurheartj.oxfordjournals.org/content/ehj/34/41/3161.full.pdf |accessdate=16 October 2020}}</ref>. He leads the Good Clinical Trial Collaborative, established by [[Wellcome Trust]], [[Bill & Melinda Gates Foundation]], and [[African Academy of Sciences]] which seeks to develop and promote the adoption of international guidelines for [[randomised control trial|randomised control trials]]. He is founding director and chair of NHS DigiTrials<ref>https://digital.nhs.uk/services/nhs-digitrials</ref>, the Health Data Research Hub for Clinical Trials hosted by [[NHS Digital]], and leads the clinical trials theme for Health Data Research UK.<ref>[https://www.hdruk.ac.uk/using-health-data/clinical-trials/]</ref>
⚫
Landray serves as co-chief investigator of the [[RECOVERY Trial]] into treatment drugs for [[COVID-19]] (the largest such clinical trial in the world) alongside [[Peter Horby]].<ref>{{Cite web|title=ISRCTN - ISRCTN50189673: A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus)|url=http://www.isrctn.com/ISRCTN50189673|access-date=2020-09-06|website=www.isrctn.com|language=en}}</ref><ref>{{cite web |title=Large-scale trial for coronavirus drugs launches in UK |url=https://www.clinicaltrialsarena.com/news/coronavirus-trial-uk-treatments/ |website=Clinical Trials Arena |access-date=7 September 2020 |date=6 April 2020}}</ref><ref>{{cite web |title=Managing clinical trials during the pandemic — Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences |url=https://www.ndorms.ox.ac.uk/news/managing-clinical-trials-during-the-pandemic |website=www.ndorms.ox.ac.uk |access-date=7 September 2020}}</ref> In June 2020, the trial discovered the first known life-saving COVID-19 drug, [[Dexamethasone]].<ref>{{Cite web|title=Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19 {{!}} University of Oxford|url=https://www.ox.ac.uk/news/2020-06-16-low-cost-dexamethasone-reduces-death-one-third-hospitalised-patients-severe|access-date=2020-09-06|website=www.ox.ac.uk}}</ref><ref>{{Cite web|title=Prime Minister's statement on coronavirus (COVID-19): 16 June 2020|url=https://www.gov.uk/government/speeches/pm-statement-at-the-coronavirus-press-conference-16-june-2020|access-date=2020-09-06|website=GOV.UK|date=16 June 2020 |language=en}}</ref><ref>{{cite journal | vauthors = Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, Chadwick D, Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Jeffery K, Montgomery A, Rowan K, Juszczak E, Baillie JK, Haynes R, Landray MJ | display-authors = 6 | title = Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report | journal = The New England Journal of Medicine | date = July 2020 | volume = 384 | issue = 8 | pages = 693–704 | pmid = 32678530 | pmc = 7383595 | doi = 10.1056/NEJMoa2021436 }}</ref> The trial also showed that [[Tocilizumab]] further reduces the risk of death for the sickest patients with COVID-19.<ref>{{cite journal |title=RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial |year=2021|pmid=33933206|author1=RECOVERY Collaborative Group|journal=Lancet|volume=397|issue=10285|pages=1637–1645|doi=10.1016/S0140-6736(21)00676-0 |issn=0140-6736 |pmc=8084355}}</ref> The trial found that a number of other treatments had no meaningful benefits for patients hospitalised with COVID-19, including [[Hydroxychloroquine]],<ref>{{cite journal |last1=Group |first1=The RECOVERY Collaborative |title=Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19 |journal=New England Journal of Medicine |date=8 October 2020 |volume=383 |issue=21 |pages=2030–2040 |doi=10.1056/NEJMoa2022926 |pmid=33031652 |pmc=7556338 |url=|language=en}}</ref> [[Lopinavir/ritonavir]],<ref>{{cite journal |last1=Horby |first1=Peter W. |last2=Mafham |first2=Marion |last3=Bell |first3=Jennifer L. |last4=Linsell |first4=Louise |last5=Staplin |first5=Natalie |last6=Emberson |first6=Jonathan |last7=Palfreeman |first7=Adrian |last8=Raw |first8=Jason |last9=Elmahi |first9=Einas |last10=Prudon |first10=Benjamin |last11=Green |first11=Christopher |last12=Carley |first12=Simon |last13=Chadwick |first13=David |last14=Davies |first14=Matthew |last15=Wise |first15=Matthew P. |last16=Baillie |first16=J. Kenneth |last17=Chappell |first17=Lucy C. |last18=Faust |first18=Saul N. |last19=Jaki |first19=Thomas |last20=Jefferey |first20=Katie |last21=Lim |first21=Wei Shen |last22=Montgomery |first22=Alan |last23=Rowan |first23=Kathryn |last24=Juszczak |first24=Edmund |last25=Haynes |first25=Richard |last26=Landray |first26=Martin J. |title=Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial |journal=The Lancet |date=5 October 2020 |volume=396 |issue=10259 |pages=1345–1352 |doi=10.1016/S0140-6736(20)32013-4 |pmid=33031764 |pmc=7535623 |url=|language=English |issn=0140-6736}}</ref> [[Azithromycin]],<ref>{{cite journal |title=Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial |year=2021|pmid=33545096|author1=RECOVERY Collaborative Group|journal=Lancet|volume=397|issue=10274|pages=605–612|doi=10.1016/S0140-6736(21)00149-5|pmc=7884931}}</ref> [[Convalescent plasma]],<ref>{{cite journal |title=Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial |year=2021|doi=10.1016/S0140-6736(21)00897-7|last1=Horby|first1=Peter W.|last2=Estcourt|first2=Lise|last3=Peto|first3=Leon|last4=Emberson|first4=Jonathan R.|last5=Staplin|first5=Natalie|last6=Spata|first6=Enti|last7=Pessoa-Amorim|first7=Guilherme|last8=Campbell|first8=Mark|last9=Roddick|first9=Alistair|last10=Brunskill|first10=Nigel E.|last11=George|first11=Tina|last12=Zehnder|first12=Daniel|last13=Tiberi|first13=Simon|last14=Aung|first14=Ni Ni|last15=Uriel|first15=Alison|last16=Widdrington|first16=John|last17=Koshy|first17=George|last18=Brown|first18=Thomas|last19=Scott|first19=Steven|last20=Baillie|first20=J Kenneth|last21=Buch|first21=Maya H.|last22=Chappell|first22=Lucy C.|last23=Day|first23=Jeremy N.|last24=Faust|first24=Saul N.|last25=Jaki|first25=Thomas|last26=Jeffery|first26=Katie|last27=Juszczak|first27=Edmund|last28=Lim|first28=Wei Shen|last29=Montgomery|first29=Alan|last30=Mumford|first30=Andrew|journal=Lancet|volume=397|issue=10289|pages=2049–2059|pmid=34000257|pmc=8121538|display-authors=1|hdl=10044/1/90411|s2cid=232168245|url=https://ora.ox.ac.uk/objects/uuid:1938e64d-23a8-4093-8f7c-0851a8bede7a|hdl-access=free}}</ref> and [[Colchicine]].<ref>{{Cite web|url=https://www.recoverytrial.net/news/recovery-trial-closes-recruitment-to-colchicine-treatment-for-patients-hospitalised-with-covid-19|title=RECOVERY trial closes recruitment to colchicine treatment for patients hospitalised with COVID-19 — RECOVERY Trial}}</ref> The trial continues to study [[REGN-COV2]] and [[Baricitinib]].<ref>{{cite web |title=Welcome — RECOVERY Trial |url=https://www.recoverytrial.net/ |website=www.recoverytrial.net |access-date=16 October 2020}}</ref>


He leads the Good Clinical Trials Collaborative, established by [[Wellcome Trust]], [[Bill & Melinda Gates Foundation]], and [[African Academy of Sciences]] which seeks to develop and promote the adoption of new international guidelines for [[randomised control trial]]s. He was previously one of the leaders of the Clinical Trial Transformation Initiative's<ref>{{cite web |url=https://www.ctti-clinicaltrials.org/ |title=Home |website=ctti-clinicaltrials.org}}</ref> risk-based monitoring,<ref>{{Cite web |url=https://www.ctti-clinicaltrials.org/sites/www.ctti-clinicaltrials.org/files/recommendations/monitoring-recommendations.pdf |title=Archived copy |access-date=2021-05-03 |archive-date=2021-05-03 |archive-url=https://web.archive.org/web/20210503154411/https://www.ctti-clinicaltrials.org/sites/www.ctti-clinicaltrials.org/files/recommendations/monitoring-recommendations.pdf |url-status=dead }}</ref> quality-by-design,<ref>{{cite web |url=https://www.ctti-clinicaltrials.org/projects/quality-design |title=Quality by Design {{!}} Clinical Trials Transformation Initiative |website=www.ctti-clinicaltrials.org |url-status=dead |archive-url=https://web.archive.org/web/20170327092841/https://www.ctti-clinicaltrials.org/projects/quality-design |archive-date=2017-03-27}}</ref> and mobile clinical trial projects.<ref>{{cite news |last1=Entis |first1=Laura |title=Can smartphone drug trials improve medical care? |url=https://www.theguardian.com/lifeandstyle/2016/jan/27/smartphone-mobile-drug-trials-fda-pfizer-ctti-depression-us-health |access-date=16 October 2020 |work=The Guardian |date=27 January 2016}}</ref> He is an advocate of streamlined approaches to clinical trial design, delivery and regulation as a means to improve healthcare.<ref>{{cite journal |title=Improving public health by improving clinical trial guidelines and their application |year=2017|pmid=28329235|last1=Landray|first1=M. J.|last2=Bax|first2=J. J.|last3=Alliot|first3=L.|last4=Buyse|first4=M.|last5=Cohen|first5=A.|last6=Collins|first6=R.|last7=Hindricks|first7=G.|last8=James|first8=S. K.|last9=Lane|first9=S.|last10=Maggioni|first10=A. P.|last11=Meeker-o'Connell|first11=A.|last12=Olsson|first12=G.|last13=Pocock|first13=S. J.|last14=Rawlins|first14=M.|last15=Sellors|first15=J.|last16=Shinagawa|first16=K.|last17=Sipido|first17=K. R.|last18=Smeeth|first18=L.|last19=Stephens|first19=R.|last20=Stewart|first20=M. W.|last21=Stough|first21=W. G.|last22=Sweeney|first22=F.|last23=Van De Werf|first23=F.|last24=Woods|first24=K.|last25=Casadei|first25=B.|journal=European Heart Journal|volume=38|issue=21|pages=1632–1637|doi=10.1093/eurheartj/ehx086|pmc=5837481}}</ref><ref>{{cite journal |title=The Magic of Randomization versus the Myth of Real-World Evidence |year=2020|pmid=32053307|last1=Collins|first1=R.|last2=Bowman|first2=L.|last3=Landray|first3=M.|last4=Peto|first4=R.|journal=The New England Journal of Medicine|volume=382|issue=7|pages=674–678|doi=10.1056/NEJMsb1901642|s2cid=211100475}}</ref> He is founding director and chair of NHS DigiTrials,<ref>{{Cite web|url=https://digital.nhs.uk/services/nhs-digitrials|title = NHS DigiTrials}}</ref> the Health Data Research Hub for Clinical Trials hosted by [[NHS Digital]], and leads the clinical trials theme for Health Data Research UK.<ref>{{Cite web|url=https://www.hdruk.ac.uk/using-health-data/clinical-trials/|title = Clinical Trials}}</ref>
⚫
In 2021, Landray was appointed to the Pandemic Preparedness Partnership (PPP), an expert group chaired by [[Patrick Vallance]] to advise the [[G7]] presidency held by the [[Government of the United Kingdom|government]] of [[Prime Minister of the United Kingdom|Prime Minister]] [[Boris Johnson]].<ref>[https://www.gov.uk/government/news/new-global-partnership-launched-to-fight-future-pandemics New global partnership launched to fight future pandemics ] [[Government of the United Kingdom]], press release of April 20, 2021.</ref>

⚫
In 2021, Landray was appointed to the Pandemic Preparedness Partnership (PPP), a group chaired by [[Patrick Vallance]] to advise the [[G7]] presidency held by the [[Government of the United Kingdom|government]] of [[Prime Minister of the United Kingdom|Prime Minister]] [[Boris Johnson]].<ref>[https://www.gov.uk/government/news/new-global-partnership-launched-to-fight-future-pandemics New global partnership launched to fight future pandemics ] [[Government of the United Kingdom]], press release of April 20, 2021.</ref>

He was [[Knight Bachelor|knighted]] in the [[2021 Birthday Honours]] for services to public health and science.<ref>{{London Gazette|issue=63377|supp=y|page=B2|date=12 June 2021}}</ref>


== Positions held ==
== Positions held ==
Landray holds the following positions:<ref>{{cite web |title=Martin Landray — Nuffield Department of Population Health |url=https://www.ndph.ox.ac.uk/team/martin-landray |website=www.ndph.ox.ac.uk |accessdate=16 October 2020}}</ref>
Landray holds the following positions:<ref>{{cite web |title=Martin Landray — Nuffield Department of Population Health |url=https://www.ndph.ox.ac.uk/team/martin-landray |website=www.ndph.ox.ac.uk |access-date=16 October 2020}}</ref>


* Professor of Medicine & Epidemiology, Nuffield Department of Population Health, University of Oxford<ref>[https://www.ndph.ox.ac.uk/]</ref>
* Professor of Medicine & Epidemiology, Nuffield Department of Population Health, University of Oxford<ref>{{cite web |url=https://www.ndph.ox.ac.uk/ |title=Home |website=ndph.ox.ac.uk}}</ref>
* Deputy Director, Big Data Institute, University of Oxford<ref>[https://www.bdi.ox.ac.uk/]</ref>
* Deputy Director, Big Data Institute, University of Oxford<ref>{{cite web |url=https://www.bdi.ox.ac.uk/ |title=Home |website=bdi.ox.ac.uk}}</ref>
* Lead, Big Data & Computing Innovation, MRC Population Health Research Unit<ref>[https://www.mrc-phru.ox.ac.uk/research/big-data-and-computing-innovation]</ref>
* Lead, Big Data & Computing Innovation, MRC Population Health Research Unit<ref>{{Cite web|url=https://www.mrc-phru.ox.ac.uk/research/big-data-and-computing-innovation|title=Big Data and Computing Innovation — Medical Research Council Population Health Research Unit (MRC PHRU)}}</ref>
* Lead, Clinical Informatics & Big Data, NIHR Oxford Biomedical Research Centre<ref>[https://oxfordbrc.nihr.ac.uk/research-themes-overview/clinical-informatics-and-big-data/]</ref>
* Lead, Clinical Informatics & Big Data, NIHR Oxford Biomedical Research Centre<ref>{{Cite web|url=https://oxfordbrc.nihr.ac.uk/research-themes-overview/clinical-informatics-and-big-data/|title = Clinical Informatics and Big Data}}</ref>
* Honorary Consultant Physician, Oxford University Hospitals NHS Foundation Trust
* Honorary Consultant Physician, Oxford University Hospitals NHS Foundation Trust

==See also==
* [[List of Old Abingdonians]]


== References ==
== References ==
Line 29: Line 42:


== External links ==
== External links ==

* [https://www.ndph.ox.ac.uk/team/martin-landray Martin Landray — Nuffield Department of Population Health]
* [https://www.ndph.ox.ac.uk/team/martin-landray Martin Landray — Nuffield Department of Population Health]
* [https://www.bdi.ox.ac.uk/Team/martin-landray Martin Landray — Oxford Big Data Institute]
* [https://www.bdi.ox.ac.uk/Team/martin-landray Martin Landray — Oxford Big Data Institute]
Line 40: Line 52:
[[Category:Living people]]
[[Category:Living people]]
[[Category:Year of birth missing (living people)]]
[[Category:Year of birth missing (living people)]]
[[Category:Knights Bachelor]]
[[Category:People educated at Abingdon School]]

Latest revision as of 12:32, 13 October 2023

Sir
Martin Landray
Bornc. 1968 (age 55–56)
Alma materAbingdon School
University of Birmingham
Scientific career
InstitutionsUniversity of Oxford
Websitewww.bdi.ox.ac.uk/Team/martin-landray

Sir Martin Jonathan Landray (born c. 1968) is a British physician, epidemiologist and data scientist who serves as a Professor of Medicine & Epidemiology at the University of Oxford. Landray designs, conducts and analyses large-scale randomised control trials; including practice-changing international trials that have recruited over 100,000 individuals.[1] Landray previously led the health informatics team that enabled the collection and management of data for the UK Biobank on over half a million people.[2]

Early life and education

[edit]

Landray was born the son of a general practitioner, Bob Landray and an anaesthetist, Margaret Bray.[3] He was educated at Abingdon School in Abingdon-on-Thames, Oxfordshire, from 1982 until 1987. He was a prefect and played rugby and cricket.[4][5] After Abingdon he went on to study medicine at the University of Birmingham, returning later for specialist training in Clinical Pharmacology & Therapeutics, and General Internal Medicine.[6]

Career

[edit]

Landray serves as co-chief investigator of the RECOVERY Trial into treatment drugs for COVID-19 (the largest such clinical trial in the world) alongside Peter Horby.[7][8][9] In June 2020, the trial discovered the first known life-saving COVID-19 drug, Dexamethasone.[10][11][12] The trial also showed that Tocilizumab further reduces the risk of death for the sickest patients with COVID-19.[13] The trial found that a number of other treatments had no meaningful benefits for patients hospitalised with COVID-19, including Hydroxychloroquine,[14] Lopinavir/ritonavir,[15] Azithromycin,[16] Convalescent plasma,[17] and Colchicine.[18] The trial continues to study REGN-COV2 and Baricitinib.[19]

He leads the Good Clinical Trials Collaborative, established by Wellcome Trust, Bill & Melinda Gates Foundation, and African Academy of Sciences which seeks to develop and promote the adoption of new international guidelines for randomised control trials. He was previously one of the leaders of the Clinical Trial Transformation Initiative's[20] risk-based monitoring,[21] quality-by-design,[22] and mobile clinical trial projects.[23] He is an advocate of streamlined approaches to clinical trial design, delivery and regulation as a means to improve healthcare.[24][25] He is founding director and chair of NHS DigiTrials,[26] the Health Data Research Hub for Clinical Trials hosted by NHS Digital, and leads the clinical trials theme for Health Data Research UK.[27]

In 2021, Landray was appointed to the Pandemic Preparedness Partnership (PPP), a group chaired by Patrick Vallance to advise the G7 presidency held by the government of Prime Minister Boris Johnson.[28]

He was knighted in the 2021 Birthday Honours for services to public health and science.[29]

Positions held

[edit]

Landray holds the following positions:[30]

  • Professor of Medicine & Epidemiology, Nuffield Department of Population Health, University of Oxford[31]
  • Deputy Director, Big Data Institute, University of Oxford[32]
  • Lead, Big Data & Computing Innovation, MRC Population Health Research Unit[33]
  • Lead, Clinical Informatics & Big Data, NIHR Oxford Biomedical Research Centre[34]
  • Honorary Consultant Physician, Oxford University Hospitals NHS Foundation Trust

See also

[edit]

References

[edit]
  1. ^ "Why the UK is ahead of the curve in the global race to find coronavirus treatments - Q&A with Martin Landray". Reaction. 22 April 2020.
  2. ^ "The challenge of saving lives with 'big data'". BBC News. 7 February 2016. Retrieved 16 October 2020.
  3. ^ "The Landry Family". Bampton Archives. Retrieved 14 June 2021.
  4. ^ "Prefects" (PDF). The Abingdonian. Retrieved 14 June 2021.
  5. ^ "Music report" (PDF). The Abingdonian. Retrieved 14 June 2021.
  6. ^ "Martin Landray". Nuffield Department of Population Health. Retrieved 14 June 2021.
  7. ^ "ISRCTN - ISRCTN50189673: A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus)". www.isrctn.com. Retrieved 2020-09-06.
  8. ^ "Large-scale trial for coronavirus drugs launches in UK". Clinical Trials Arena. 6 April 2020. Retrieved 7 September 2020.
  9. ^ "Managing clinical trials during the pandemic — Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences". www.ndorms.ox.ac.uk. Retrieved 7 September 2020.
  10. ^ "Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19 | University of Oxford". www.ox.ac.uk. Retrieved 2020-09-06.
  11. ^ "Prime Minister's statement on coronavirus (COVID-19): 16 June 2020". GOV.UK. 16 June 2020. Retrieved 2020-09-06.
  12. ^ Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. (July 2020). "Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report". The New England Journal of Medicine. 384 (8): 693–704. doi:10.1056/NEJMoa2021436. PMC 7383595. PMID 32678530.
  13. ^ RECOVERY Collaborative Group (2021). "RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial". Lancet. 397 (10285): 1637–1645. doi:10.1016/S0140-6736(21)00676-0. ISSN 0140-6736. PMC 8084355. PMID 33933206.
  14. ^ Group, The RECOVERY Collaborative (8 October 2020). "Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19". New England Journal of Medicine. 383 (21): 2030–2040. doi:10.1056/NEJMoa2022926. PMC 7556338. PMID 33031652. {{cite journal}}: |last1= has generic name (help)
  15. ^ Horby, Peter W.; Mafham, Marion; Bell, Jennifer L.; Linsell, Louise; Staplin, Natalie; Emberson, Jonathan; Palfreeman, Adrian; Raw, Jason; Elmahi, Einas; Prudon, Benjamin; Green, Christopher; Carley, Simon; Chadwick, David; Davies, Matthew; Wise, Matthew P.; Baillie, J. Kenneth; Chappell, Lucy C.; Faust, Saul N.; Jaki, Thomas; Jefferey, Katie; Lim, Wei Shen; Montgomery, Alan; Rowan, Kathryn; Juszczak, Edmund; Haynes, Richard; Landray, Martin J. (5 October 2020). "Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial". The Lancet. 396 (10259): 1345–1352. doi:10.1016/S0140-6736(20)32013-4. ISSN 0140-6736. PMC 7535623. PMID 33031764.
  16. ^ RECOVERY Collaborative Group (2021). "Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial". Lancet. 397 (10274): 605–612. doi:10.1016/S0140-6736(21)00149-5. PMC 7884931. PMID 33545096.
  17. ^ Horby, Peter W.; et al. (2021). "Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial". Lancet. 397 (10289): 2049–2059. doi:10.1016/S0140-6736(21)00897-7. hdl:10044/1/90411. PMC 8121538. PMID 34000257. S2CID 232168245.
  18. ^ "RECOVERY trial closes recruitment to colchicine treatment for patients hospitalised with COVID-19 — RECOVERY Trial".
  19. ^ "Welcome — RECOVERY Trial". www.recoverytrial.net. Retrieved 16 October 2020.
  20. ^ "Home". ctti-clinicaltrials.org.
  21. ^ "Archived copy" (PDF). Archived from the original (PDF) on 2021-05-03. Retrieved 2021-05-03.{{cite web}}: CS1 maint: archived copy as title (link)
  22. ^ "Quality by Design | Clinical Trials Transformation Initiative". www.ctti-clinicaltrials.org. Archived from the original on 2017-03-27.
  23. ^ Entis, Laura (27 January 2016). "Can smartphone drug trials improve medical care?". The Guardian. Retrieved 16 October 2020.
  24. ^ Landray, M. J.; Bax, J. J.; Alliot, L.; Buyse, M.; Cohen, A.; Collins, R.; Hindricks, G.; James, S. K.; Lane, S.; Maggioni, A. P.; Meeker-o'Connell, A.; Olsson, G.; Pocock, S. J.; Rawlins, M.; Sellors, J.; Shinagawa, K.; Sipido, K. R.; Smeeth, L.; Stephens, R.; Stewart, M. W.; Stough, W. G.; Sweeney, F.; Van De Werf, F.; Woods, K.; Casadei, B. (2017). "Improving public health by improving clinical trial guidelines and their application". European Heart Journal. 38 (21): 1632–1637. doi:10.1093/eurheartj/ehx086. PMC 5837481. PMID 28329235.
  25. ^ Collins, R.; Bowman, L.; Landray, M.; Peto, R. (2020). "The Magic of Randomization versus the Myth of Real-World Evidence". The New England Journal of Medicine. 382 (7): 674–678. doi:10.1056/NEJMsb1901642. PMID 32053307. S2CID 211100475.
  26. ^ "NHS DigiTrials".
  27. ^ "Clinical Trials".
  28. ^ New global partnership launched to fight future pandemics Government of the United Kingdom, press release of April 20, 2021.
  29. ^ "No. 63377". The London Gazette (Supplement). 12 June 2021. p. B2.
  30. ^ "Martin Landray — Nuffield Department of Population Health". www.ndph.ox.ac.uk. Retrieved 16 October 2020.
  31. ^ "Home". ndph.ox.ac.uk.
  32. ^ "Home". bdi.ox.ac.uk.
  33. ^ "Big Data and Computing Innovation — Medical Research Council Population Health Research Unit (MRC PHRU)".
  34. ^ "Clinical Informatics and Big Data".
[edit]
Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Martin_Landray&oldid=1179938077"